Amarenco, P.

aspirin patient trial aspirin dose disease death mortality lotrafiban stroke event aspirin doses platelet robert /iiia swets subs service all-cause mortality hazard study infarction bravo end point ischemic table randomized group cerebrovascular disease signi ficantly circulation david ն162 mg /day lotrafiban group heart university signi figure point placebo cerebrovascular william ͻ162 mg /day glycoprotein all-cause revascularization michael topol dosing placebo group hospital ͻ0.001 162 mg /d martin syndrome reduction receptor american incidence pierre therapy bravo trial creatinine clearance service outcome ficantly antagonist model assoc safety monitoring board 325 mg /d downloaded result february nonfatal stephen treatment 50 mg bid circ.ahajournals.org ischemic attack effect jeffrey complication